<DOC>
	<DOCNO>NCT00198146</DOCNO>
	<brief_summary>The primary purpose study determine efficacy safety daclizumab prevent progression diabetes child diagnose type I diabetes . Additional purpose study investigate amount drug child , quickly eliminate blood , analyze effect drug immune reaction diabetes .</brief_summary>
	<brief_title>Prevention Diabetes Progression Trial ( PDPT )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Newly diagnose type 1 diabetes without previous insulin oral hypoglycemic therapy . age 2 40 year diagnosis enroll within 3 month diagnosis test positive least one biochemical autoantibody ( ICA512 , GAD 65 IAA ) prior enrol Previous treatment antiIL2 direct monoclonal antibody investigational agent would interfere ability evaluate safety efficacy daclizumab . Other immunosuppressive drug include , limited , corticosteroid , cyclosporine , tacrolimus , rapamycin , mycophenolate mofetil , azathioprine . Active significant infection Limited life expectancy disease diabetes Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>